Tom Fraine, Equity Analyst at Shore Capital, analyzes Accrol Group Holdings' acquisition of Severn Delta. He highlights the positive business potential and strategic growth opportunities for the company. The planned self-funded investment in a paper mill is expected to drive further margin increases. Accrol's strong performance, low capex requirements, and favorable market conditions position it for continued success...
Syncona Ltd notes further safety and enzyme activity data from its portfolio company, Freeline Therapeutics, on its gene therapy candidate for Gaucher disease...
Versarien plc has raised £400,000 through a placing of new shares, with the net proceeds to be used for capital purposes and seizing growth opportunities...
Tom Fraine, Equity Analyst at Shore Capital, analyzes Accrol Group Holdings' acquisition of Severn Delta. He highlights the positive business potential and strategic growth opportunities for the company. The planned self-funded investment in a paper mill is expected to drive further margin increases. Accrol's strong performance, low capex requirements, and favorable market conditions position it for continued success...
Syncona Ltd notes further safety and enzyme activity data from its portfolio company, Freeline Therapeutics, on its gene therapy candidate for Gaucher disease...
Versarien plc has raised £400,000 through a placing of new shares, with the net proceeds to be used for capital purposes and seizing growth opportunities...
